| Budget Amount *help |
¥18,330,000 (Direct Cost: ¥14,100,000、Indirect Cost: ¥4,230,000)
Fiscal Year 2012: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2011: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
Fiscal Year 2010: ¥6,240,000 (Direct Cost: ¥4,800,000、Indirect Cost: ¥1,440,000)
|
|---|
| Research Abstract |
We developed a phospholamban specific RNA aptamer as a novel inotropic and lucitropic agent to treat heart failure. The obtained aptamer increased Ca2+ uptake by cardiac sarcoplasmic reticulum in the nanomolar range. To introduce it into cardiomyocytes, we conjugated a membrane penetrating peptide to the aptamer. This aptamer facilitated contraction as well as relaxation of isolated cardiomyocytes. Furthermore, the aptamer improved cardiac functions in vivo. A membrane penetrating peptide-conjugated phospholamban aptamer is thus a potent inotropic and lucitropic agent and could be a novel drug for heart failure.
|
